Literatur
Li M et al. J Clin Endocrinol Metab. 2014;99(7):2327–36.
Pfreundschuh M et al. Lancet Oncol. 2008;9(2):105–16.
Held G et al. J Clin Oncol. 2014;32(11):1112–8.
Liu PT et al. Science. 2006;311(5768):1770–3.
Gröber U et al. Dermatoendocrinol. 2013;5(3):331–47.
Reid D et al. Am J Clin Nutr. 2011;93(5):1006–11.
Wayse V et al. Eur J Clin Nutr. 2004;58(4):563–7.
Manaseki-Holland S et al. Lancet. 2012;379(9824):1419–27.
Camargo CA Jr et al. Pediatrics. 2012;130(3):e561–7.
Sabetta JR et al. PLoS One. 2010;5(6):e11088.
Murdoch DR et al. JAMA. 2012;308(13):1333–9.
Zeichner SB et al. Clin Breast Cancer. 2015;15(1):e1–e11.
Originalie
Bittenbring JT et al. Vitamin D deficiency impairs rituximabmediated cellular cytotoxicity and outcome of patients with diffuse large B-cell lymphoma treated with but not without rituximab. J Clin Oncol. 2014;32(29):3242-8.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Fink, M. Vitamin-D-Mangel vermindert Rituximab-Wirkung bei DLBCL. Info Onkol. 18, 17–19 (2015). https://doi.org/10.1007/s15004-015-0721-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s15004-015-0721-0